Keytruda Boosts Seven-Year Survival in Triple-Negative Breast Cancer

For patients with high-risk, early-stage triple-negative breast cancer (TNBC), the addition of the immunotherapy drug Keytruda (pembrolizumab) to standard chemotherapy is no longer just an option. It is, according to an expert discussing the latest data, the definitive standard of care.

New findings from the final analysis of the KEYNOTE-522 trial, presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, show that this treatment combination significantly improves long-term survival, with benefit sustained nearly eight years after treatment.

The study followed 1,174 patients for a median of 93.8 months. Researchers found that the seven-year overall survival rate was 85.1% for those who received Keytruda alongside chemotherapy before surgery (neoadjuvant treatment) and as a single agent after surgery (adjuvant treatment). In contrast, the survival rate was 77.2% for those who received chemotherapy and a placebo.

“Yesterday, the standard of care was chemotherapy, today the standard case [is] chemotherapy plus [Keytruda],” said Dr. Javier Cortes, a leading breast cancer expert and presenter at the meeting, in an interview conducted prior to the meeting.

A path to cure

Triple-negative breast cancer is known for being more aggressive than other subtypes. For patients with stage 2 or stage 3 disease, typically characterized by tumors larger than 10 millimeters or lymph node involvement, the goal is not just management, but a cure.

Cortes noted three primary reasons why this regimen has shifted the treatment landscape.

First, it increases the likelihood of a pathological complete remission, meaning no visible cancer remains at the time of surgery. “After surgery we will not need more chemotherapy for sure,” Cortes said regarding patients who achieve this status. Second, the treatment decreases the risk of the cancer spreading to other parts of the body. “The best prognosis of metastasis are the ones which have not developed,” Cortes added. Finally, and most importantly for patients, the data shows a higher chance of being cured

Reference:

“Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for high-risk early-stage TNBC: Final analysis results from the phase 3 KEYNOTE-522 study,” presented by Dr. Javier Cortes at the 2026 American Society of Clinical Oncology Annual Meeting; May 29-June 2, 2026; Chicago, IL.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.